Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00464776
Recruitment Status : Completed
First Posted : April 24, 2007
Last Update Posted : February 4, 2011
Information provided by:

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : April 2008
  Study Completion Date : No date given